Back

Frequency of gout adverse events with bempedoic acid or placebo in those receiving uric acid lowering therapies as prophylaxis or treatment after a gout episode - insights from CLEAR outcomes

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Refining efficacy and safety of lipid-lowering pharmacotherapy Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Efficacy and safty of a quadruple combination of amlodipine, losartan, rosuvastatin, and ezetimibe in ASCVD patients with poor medication adherence (AMOREMIO study)
Assistant Professor M. Chon (Yangsan, KR)
Abstract Slides Video
Presentation thumbnail
Resistance to lipid-lowering therapy with PCSK9 inhibitors: comparative efficacy and clinical implications
Assistant Professor W. Streb (Zabrze, PL)
Abstract Slides Video
Presentation thumbnail
Impact of elevated lipoprotein(a) on LDL-C lowering efficacy in ACS patients undergoing triple lipid-lowering therapy: insights from LAI-REACT-LP(a) sub-study
Doctor K. Mahajan (Mandi, IN)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of pemafibrate in patients with statin-intolerant hypercholesterolemia: results from a 12-week, randomized, double blind, placebo-controlled, phase 3 trial
Professor S. Yamashita (Izumisano, JP)
Abstract Slides Video
Presentation thumbnail
Triple oral lipid-lowering treatment pathway and associated outcomes in high- and very high-cv risk patients: a simulation using the SANTORINI study cohort
Doctor J. Katzmann (Leipzig, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Refining efficacy and safety of lipid-lowering pharmacotherapy
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
Refining efficacy and safety of lipid-lowering pharmacotherapy
thumbnail
Congress Session
Clinical trial updates on prevention and lipid lowering
thumbnail
Congress Session
Latest advancements in low-density lipoprotein cholesterol (LDL-C) lowering therapies and cardiovascular outcome trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources